Tom Curran, PhD, FRS, of The Children’s Hospital of Philadelphia Research Institute, contributed to an article in the Journal of Clinical Oncology assessing the efficacy of a drug called vismodegib (Erivedge) in a subgroup of patients with recurrent medulloblastoma.
